187 related articles for article (PubMed ID: 38657595)
1. [Innovative therapies for treatment of invasive fungal diseases].
Mellinghoff SC; Cornely OA; Mammadova P; Sprute R; Stemler J
Dtsch Med Wochenschr; 2024 May; 149(10):560-568. PubMed ID: 38657595
[TBL] [Abstract][Full Text] [Related]
2. Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective.
Lamoth F; Lewis RE; Kontoyiannis DP
Clin Infect Dis; 2022 Aug; 75(3):534-544. PubMed ID: 34986246
[TBL] [Abstract][Full Text] [Related]
3. New treatment options for critically important WHO fungal priority pathogens.
Kriegl L; Egger M; Boyer J; Hoenigl M; Krause R
Clin Microbiol Infect; 2024 Mar; ():. PubMed ID: 38461942
[TBL] [Abstract][Full Text] [Related]
4. The antifungal pipeline for invasive fungal diseases: what does the future hold?
Neoh CF; Jeong W; Kong DC; Slavin MA
Expert Rev Anti Infect Ther; 2023 Jun; 21(6):577-594. PubMed ID: 37057677
[TBL] [Abstract][Full Text] [Related]
5. Emerging Diagnostics and Therapeutics for Invasive Fungal Infections.
Friedman DZP; Schwartz IS
Infect Dis Clin North Am; 2023 Sep; 37(3):593-616. PubMed ID: 37532392
[TBL] [Abstract][Full Text] [Related]
6. Pipeline of Novel Antifungals for Invasive Fungal Disease in Transplant Recipients: A Pediatric Perspective.
Hsu AJ; Hanisch BR; Fisher BT; Huppler AR
J Pediatric Infect Dis Soc; 2024 Feb; 13(Supplement_1):S68-S79. PubMed ID: 38417087
[TBL] [Abstract][Full Text] [Related]
7. Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.
Aruanno M; Glampedakis E; Lamoth F
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138565
[TBL] [Abstract][Full Text] [Related]
8. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.
Hoenigl M; Sprute R; Egger M; Arastehfar A; Cornely OA; Krause R; Lass-Flörl C; Prattes J; Spec A; Thompson GR; Wiederhold N; Jenks JD
Drugs; 2021 Oct; 81(15):1703-1729. PubMed ID: 34626339
[TBL] [Abstract][Full Text] [Related]
9. How urgent is the need for new antifungals?
Stewart AG; Paterson DL
Expert Opin Pharmacother; 2021 Oct; 22(14):1857-1870. PubMed ID: 34231434
[No Abstract] [Full Text] [Related]
10. Treatment of Invasive Aspergillosis: How It's Going, Where It's Heading.
Boyer J; Feys S; Zsifkovits I; Hoenigl M; Egger M
Mycopathologia; 2023 Oct; 188(5):667-681. PubMed ID: 37100963
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and
Miesel L; Cushion MT; Ashbaugh A; Lopez SR; Ong V
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318018
[TBL] [Abstract][Full Text] [Related]
12. Future Fungal Fighters in Dermatology: Novel Antifungal Drug Pipeline.
Khalfe Y; Rosen T
J Drugs Dermatol; 2022 May; 21(5):496-501. PubMed ID: 35533026
[TBL] [Abstract][Full Text] [Related]
13. Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections.
Angulo DA; Alexander B; Rautemaa-Richardson R; Alastruey-Izquierdo A; Hoenigl M; Ibrahim AS; Ghannoum MA; King TR; Azie NE; Walsh TJ
J Fungi (Basel); 2022 Oct; 8(11):. PubMed ID: 36354888
[TBL] [Abstract][Full Text] [Related]
14. Antifungal resistance, combinations and pipeline: oh my!
Stover KR; Hawkins BK; Keck JM; Barber KE; Cretella DA
Drugs Context; 2023; 12():. PubMed ID: 38021410
[TBL] [Abstract][Full Text] [Related]
15. A Heat-Killed
Wang Y; Wang K; Masso-Silva JA; Rivera A; Xue C
mBio; 2019 Nov; 10(6):. PubMed ID: 31772051
[No Abstract] [Full Text] [Related]
16. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
17. Intensive care medicine research agenda on invasive fungal infection in critically ill patients.
Bassetti M; Garnacho-Montero J; Calandra T; Kullberg B; Dimopoulos G; Azoulay E; Chakrabarti A; Kett D; Leon C; Ostrosky-Zeichner L; Sanguinetti M; Timsit JF; Richardson MD; Shorr A; Cornely OA
Intensive Care Med; 2017 Sep; 43(9):1225-1238. PubMed ID: 28255613
[TBL] [Abstract][Full Text] [Related]
18. [Anti-infective treatment of fungal infections by Candida and Aspergillus].
Salzer HJF
Med Klin Intensivmed Notfmed; 2023 Sep; 118(6):470-476. PubMed ID: 37644243
[TBL] [Abstract][Full Text] [Related]
19. Interpretation, pitfalls of biomarkers in diagnosis of invasive fungal diseases.
Lass-Florl C; Alastruey-Izquierdo A; Gupta R; Chakroborti A
Indian J Med Microbiol; 2022; 40(4):480-484. PubMed ID: 35970627
[TBL] [Abstract][Full Text] [Related]
20. Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.
Hoenigl M; Sprute R; Arastehfar A; Perfect JR; Lass-Flörl C; Bellmann R; Prattes J; Thompson GR; Wiederhold NP; Al Obaidi MM; Willinger B; Arendrup MC; Koehler P; Oliverio M; Egger M; Schwartz IS; Cornely OA; Pappas PG; Krause R
Expert Opin Investig Drugs; 2022 Aug; 31(8):795-812. PubMed ID: 35657026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
